MA41668A1 - Composition multi-pertidique - Google Patents

Composition multi-pertidique

Info

Publication number
MA41668A1
MA41668A1 MA41668A MA41668A MA41668A1 MA 41668 A1 MA41668 A1 MA 41668A1 MA 41668 A MA41668 A MA 41668A MA 41668 A MA41668 A MA 41668A MA 41668 A1 MA41668 A1 MA 41668A1
Authority
MA
Morocco
Prior art keywords
peptide combination
composition
pertidic
relates
specific peptide
Prior art date
Application number
MA41668A
Other languages
English (en)
Inventor
Mark Peakman
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Publication of MA41668A1 publication Critical patent/MA41668A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

L'invention concerne une combinaison peptidique spécifique. La combinaison peptidique peut être présente dans une composition pharmaceutiquement acceptable. La combinaison peptidique peut être utilisée dans la thérapie ou la prévention du diabète type 1 (did). L'invention concerne également une méthode de diagnostic ou de détermination de l'efficacité d'un traitement, la méthode faisant appel à la combinaison peptidique spécifique.
MA41668A 2015-06-10 2016-06-10 Composition multi-pertidique MA41668A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1510056.3A GB201510056D0 (en) 2015-06-10 2015-06-10 Multi-peptide composition
PCT/GB2016/051726 WO2016198887A1 (fr) 2015-06-10 2016-06-10 Composition multi-peptidique

Publications (1)

Publication Number Publication Date
MA41668A1 true MA41668A1 (fr) 2018-03-30

Family

ID=53785229

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41668A MA41668A1 (fr) 2015-06-10 2016-06-10 Composition multi-pertidique

Country Status (26)

Country Link
US (1) US11400131B2 (fr)
EP (1) EP3307298B1 (fr)
JP (1) JP6969790B2 (fr)
KR (1) KR20180023948A (fr)
CN (1) CN107896494B (fr)
AR (1) AR104947A1 (fr)
AU (1) AU2016275295B2 (fr)
BR (1) BR112017026537A2 (fr)
CL (1) CL2017003143A1 (fr)
CO (1) CO2017012986A2 (fr)
EA (1) EA201890007A1 (fr)
EC (1) ECSP18001655A (fr)
ES (1) ES2778630T3 (fr)
GB (1) GB201510056D0 (fr)
HK (1) HK1253094A1 (fr)
IL (1) IL256199B2 (fr)
MA (1) MA41668A1 (fr)
MX (1) MX2017015658A (fr)
PE (1) PE20180450A1 (fr)
PH (1) PH12017501918A1 (fr)
PL (1) PL3307298T3 (fr)
TN (1) TN2017000517A1 (fr)
TW (1) TW201712027A (fr)
UY (1) UY36722A (fr)
WO (1) WO2016198887A1 (fr)
ZA (1) ZA201707873B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542488A (ja) * 1999-04-21 2002-12-10 ザイコス インク． 疾患を促進するｃｄ４＋ｔリンパ球によって認識されるペプチドエピトープ
US20030045467A1 (en) * 2001-01-05 2003-03-06 Tihamer Orban Autoantigen composition
GB0402129D0 (en) * 2004-01-30 2004-03-03 King S College London Therapeutic and diagnostic peptides
EP1709070B1 (fr) * 2004-01-30 2013-05-29 King's College London Peptides pour le traitement de maladies auto-immunes
AU2005213449A1 (en) * 2004-02-04 2005-08-25 The La Jolla Institute For Allergy And Immunology Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
WO2008083331A2 (fr) * 2006-12-29 2008-07-10 The Regents Of The University Of Colorado Diagnostic et cible thérapeutique pour des maladies autoimmunes et leurs utilisations
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
CN104203263A (zh) * 2012-03-01 2014-12-10 耶达研究与发展有限公司 利用HSP60衍生肽再生胰岛β细胞

Also Published As

Publication number Publication date
WO2016198887A1 (fr) 2016-12-15
HK1253094A1 (zh) 2019-06-06
AU2016275295B2 (en) 2021-12-09
EA201890007A1 (ru) 2018-05-31
EP3307298A1 (fr) 2018-04-18
CA2984957A1 (fr) 2016-12-15
AU2016275295A1 (en) 2017-12-07
JP6969790B2 (ja) 2021-11-24
CN107896494B (zh) 2021-09-03
ECSP18001655A (es) 2018-10-31
IL256199B2 (en) 2024-11-01
US11400131B2 (en) 2022-08-02
TN2017000517A1 (en) 2019-04-12
US20180221434A1 (en) 2018-08-09
CN107896494A (zh) 2018-04-10
JP2018524301A (ja) 2018-08-30
GB201510056D0 (en) 2015-07-22
PE20180450A1 (es) 2018-03-05
ES2778630T3 (es) 2020-08-11
PH12017501918A1 (en) 2018-03-19
IL256199A (en) 2018-02-28
UY36722A (es) 2017-01-31
AR104947A1 (es) 2017-08-23
IL256199B1 (en) 2024-07-01
KR20180023948A (ko) 2018-03-07
TW201712027A (zh) 2017-04-01
MX2017015658A (es) 2018-08-15
BR112017026537A2 (pt) 2019-11-12
CO2017012986A2 (es) 2018-03-09
PL3307298T3 (pl) 2020-06-29
CL2017003143A1 (es) 2018-05-18
EP3307298B1 (fr) 2020-01-15
ZA201707873B (en) 2019-05-29

Similar Documents

Publication Publication Date Title
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA43518B1 (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
MA47399A (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
JOP20220056A1 (ar) مركبات rip1 تثبيطية وطرق عملها واستخدامها
MA52216B1 (fr) Mirikizumab pour le traitement de la colite ulcéreuse
MA42439B1 (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MX376077B (es) Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
MA41634B1 (fr) Formulation à base de combinaison de tésofensine et de métoprolol
MX2017014204A (es) Formulaciones de tpp1 y metodos para tratar la enfemedad de cln2.
MX376312B (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash
MX2016016139A (es) Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.
MA46548A (fr) Fsh pour le traitement de l'infertilité
WO2015112902A3 (fr) Inhibiteurs de cystathionine- (gamma)-lyase (cse) pour le traitement de la douleur
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
MX2018013812A (es) Compuestos moduladores del receptor adrenérgico y sus métodos de uso.
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA49396B1 (fr) Traitement de la migraine avec acétyl-leucine
EA201790609A1 (ru) Макроциклические ингибиторы rip2-киназы
FR3061021B1 (fr) Antagoniste specifique de tlr4 dans le traitement du myelome multiple
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2021012848A (es) Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main